Study Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-CDH17 CAR-T cell injection in patients with CDH17-positive advanced malignant solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
Anti-CDH17 CAR-T cellsBIOLOGICAL
Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shanghai Pudong hospital | Shanghai | Shanghai Municipality | China |